EUVIMEDEUVIMED entdecken
Open Access

Immune Checkpoint Inhibitor–Associated Acute Kidney Injury

Shruti Gupta iD, Roberta Fenoglio iD, Naoka Murakami iD, Elad Sharon iD, Sandra M Herrmann iD, Biruh T Workeneh, Dario Roccatello, Jack A Blau, Marlies Ostermann iD, Claudio Ronco iD, Amanda DeMauro Renaghan iD, Mitchell H Rosner iD und 2 weitere

Journal of the American Society of Nephrology · 2026-10 · 37 (10) · 2329-2344

DOI: 10.1681/asn.0000001232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 31.07.2026. Verfasst von Shruti Gupta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Acute Kidney Injury, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with immune-related adverse events, including ICI-associated AKI (ICI-AKI). ICI-AKI presents diagnostic and management challenges and can influence decisions regarding immunosuppression and ICI rechallenge, with important implications for both kidney and cancer outcomes. An international, multidisciplinary panel convened at the 34th Acute Disease Quality Initiative (ADQI) consensus conference in September 2024. Systematic literature searches of PubMed were conducted to identify studies on the epidemiology, mechanisms, diagnosis, management, rechallenge, and outcomes of ICI-AKI. The meeting followed the established ADQI process and used a modified Delphi method to achieve consensus. Evidence was reviewed and appraised by workgroups, and consensus statements were developed through structured discussion and voting. Observational data suggest that AKI occurs in up to 20% of patients receiving ICIs, with ICI-AKI accounting for approximately 2%–5% of cases. Acute tubulointerstitial nephritis is the most common lesion, observed in 80%–90% of biopsies, although glomerular diseases are increasingly recognized. No clinical features reliably distinguish ICI-AKI from other causes of AKI, and kidney biopsy remains the diagnostic gold standard. Emerging urinary, circulating, and imaging biomarkers show promise but are not yet ready for routine clinical use. Early glucocorticoid initiation (within 3 days of ICI-AKI diagnosis versus >3 days after diagnosis) is associated with higher rates of kidney recovery, although optimal dosing and duration remain uncertain. Recurrent ICI-AKI occurs in fewer than 20% of patients undergoing ICI rechallenge. Management of high-risk populations, including kidney transplant recipients and patients with autoimmune disease or advanced CKD, requires individualized, multidisciplinary decision making. ICI-AKI is an important and potentially reversible complication of cancer immunotherapy; these consensus statements provide a framework for diagnosis and management, support cautious ICI rechallenge in selected patients, and identify priorities for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryImmune Checkpoint InhibitorsHumans

Stichwörter der Autor:innen

AKIacute kidney failureclinical nephrology

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts.
  • Department of Clinical and Biological Sciences, University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member), Nephrology and Dialysis Unit and Center of Im…
  • Division of Nephrology, Washington University in St. Louis, St. Louis, Missouri.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

ORCID-Profile: Shruti Gupta, Roberta Fenoglio, Naoka Murakami, Elad Sharon, Sandra M Herrmann, Marlies Ostermann, Claudio Ronco, Amanda DeMauro Renaghan, Mitchell H Rosner

Zitieren

APA

Gupta, S., Fenoglio, R., Murakami, N., Sharon, E., Herrmann, S. M., Workeneh, B. T., Roccatello, D., Blau, J. A., Ostermann, M., Ronco, C., Renaghan, A. D., Rosner, M. H., Leaf, D. E., & on behalf of the ADQI Conference Participants (2026). Immune Checkpoint Inhibitor–Associated Acute Kidney Injury. Journal of the American Society of Nephrology, 37(10), 2329-2344. https://doi.org/10.1681/asn.0000001232

Vancouver

Gupta S, Fenoglio R, Murakami N, Sharon E, Herrmann SM, Workeneh BT, et al. Immune Checkpoint Inhibitor–Associated Acute Kidney Injury. Journal of the American Society of Nephrology. 2026;37(10):2329-2344. doi:10.1681/asn.0000001232

BibTeX
@article{Gupta2026,
  author = {Gupta, Shruti and Fenoglio, Roberta and Murakami, Naoka and Sharon, Elad and Herrmann, Sandra M and Workeneh, Biruh T and Roccatello, Dario and Blau, Jack A and Ostermann, Marlies and Ronco, Claudio and Renaghan, Amanda DeMauro and Rosner, Mitchell H and Leaf, David E and on behalf of the ADQI Conference Participants, on behalf of the ADQI Conference Participants},
  title = {Immune Checkpoint Inhibitor–Associated Acute Kidney Injury},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  volume = {37},
  number = {10},
  pages = {2329--2344},
  doi = {10.1681/asn.0000001232}
}
Kostenlos starten →